Impact of restrictive measures due to the Covid-19 pandemic on the incidence of immune thrombocytopenia in children: an Italian single center experience

Ceglie, Giulia; Musolino, Antonino; Clemente, Vitangelo; Marchesani, Silvio; Gennaro, Francesca; Paganelli, Valeria; Palumbo, Giuseppe

doi:10.1080/08880018.2022.2095473

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Another single-center study reported that newly diagnosed thrombocytopenia in children decreased during the lockdown due to the pandemic, probably because of barrier measures that had reduced the incidence of viral triggers thought to be responsible for the vast majority of ITP cases involving children. 21 In the present study, we analyzed the incidence of ITP and severe ITP by age group during a period of decreased viral infections due to NPI to predict the degree to which viral infections contribute to ITP in each age group.…”

Section: Discussionmentioning

confidence: 99%

Changes in the Incidence of Immune Thrombocytopenia in the Coronavirus Disease 2019 Era: A Nationwide Observational Study in Korea

Choi¹,

Jung²,

Kim³

et al. 2023

RMHP

View full text Add to dashboard Cite

We investigated whether nonpharmaceutical interventions (NPI) to reduce the spread of coronavirus disease 2019 (COVID-19) was associated with a change in the incidence of immune thrombocytopenia (ITP). Patients and Methods: Using the Korean Health Insurance Review and Assessment Services (HIRA) database, individuals newly diagnosed with ITP between January 2015 and December 2020 were identified. The NPI period was defined as February 2020 to December 2020. The ITP incidence in the NPI period was compared with the mean annual incidence during the same months in the pre-NPI period and the incidence predicted by the autoregressive integrated moving average model. Results: In total, 25,723 patients were identified, and the overall annual incidence of ITP was 8.28 per 100,000 persons ([95% confidence interval (CI): 8.18-8.39]. The ITP incidence in the NPI period was 6.60 per 100,000 person-years (95% CI: 6.37-6.85), 0.77 times (95% CI: 0.74-0.80) lower than that during the pre-NPI period [8.62/100,000 (95% CI: 8.50−8.74)]. With the exception for patients aged ≥70 years, the ITP incidence was significantly lower in the NPI period than in the pre-NPI period. The most significant decline in the ITP incidence during the NPI period was observed in the 0-9 years age group [25.76/100,000 vs 14.01/100,000, P <0.001; incidence rate ratio (IRR): 0.54 (95% CI: 0.51-0.58)]. The intravenous immunoglobulin-treated ITP incidence in the NPI period was 1.69/100,000 (95% CI: 1.58-1.81), 0.79 times (95% CI: 0.73-0.85) lower than that in the pre-NPI period 2.15/100,000 (95% CI: 2.09−2.21)]. The incidence of steroid-treated ITP was lower in the NPI period than in the pre-NPI period (2.73/100,000 vs 2.2/100,000, P <0.001), with an IRR of 0.80 (95% CI: 0.76-0.83). Conclusion:This nationwide study revealed a significant decrease in ITP incidence, particularly among children, after the implementation of NPI.

show abstract

Section: Discussionmentioning

confidence: 99%